230301-81-2 Usage
Uses
Used in Pharmaceutical Industry:
3-Fluoro-2-methyl-benzoic acid methyl ester is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Fluoro-2-methyl-benzoic acid methyl ester is utilized as a precursor in the production of agrochemicals, potentially enhancing crop protection and yield through its incorporation into various formulations.
Used in Specialty Chemicals Production:
3-Fluoro-2-methyl-benzoic acid methyl ester is employed as an intermediate in the manufacturing of specialty chemicals, where its unique chemical structure can be leveraged to create compounds with tailored properties for specific applications.
Used in Materials Science:
3-Fluoro-2-methyl-benzoic acid methyl ester may be used in materials science for the development of new materials with improved characteristics, such as enhanced stability or specific interactions with other molecules, due to its distinct structural features.
Used in Organic Synthesis:
As a component in organic synthesis, 3-Fluoro-2-methyl-benzoic acid methyl ester is used as a building block for creating a variety of organic compounds, contributing to the advancement of chemical research and the discovery of novel chemical entities.
Check Digit Verification of cas no
The CAS Registry Mumber 230301-81-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,3,0,3,0 and 1 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 230301-81:
(8*2)+(7*3)+(6*0)+(5*3)+(4*0)+(3*1)+(2*8)+(1*1)=72
72 % 10 = 2
So 230301-81-2 is a valid CAS Registry Number.
InChI:InChI=1/C9H9FO2/c1-6-7(9(11)12-2)4-3-5-8(6)10/h3-5H,1-2H3
230301-81-2Relevant academic research and scientific papers
SPIROCYCLIC TETRAHYDROQUINAZOLINES
-
Paragraph 0722; 0725-0727, (2021/07/17)
Provided are compounds represented by Formula I, wherein R3, A, A1, A2, A3, E, E1, E2, L, Q, Z, and (aa) are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Formula (I) are KRAS inhibitors and are thus useful to treat cancer and other diseases.
Spirocyclic tetrahydroquinazolines
-
Paragraph 1019; 1024-1026, (2021/07/11)
The invention discloses spirocyclic tetrahydroquinazolines , and particularly provide compounds represented by Formula I shown in the specification, and pharmaceutically acceptable salts and solvates thereof. In the formula, R3, A, A1, A2, A3, E, E1, E2, L, Q, Z and a structure shown in the specification are as defined in the specification,. The compounds of formula I are KRAS inhibitors and are therefore useful in the treatment of cancer and other diseases.
HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
-
Page/Page column 70, (2020/07/14)
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
ISOINDOLINONE DERIVATIVES
-
Page/Page column 18, (2012/11/13)
The present invention relates to compounds of the formula I, as well as pharmaceutically-acceptable salts thereof, pharmaceutical compositions containing said compounds and methods of using said compounds in the treatment or prophylaxis of diseases and disorders. The compounds and compositions disclosed herein are glucokinase activators useful for the treatment or prophylaxis of metabolic diseases and disorders, for example diabetes mellitus, including type II diabetes mellitus.
